2018
TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD—A Novel Presentation
Gulati A, Bale AE, Dykas DJ, Bia MJ, Danovitch GM, Moeckel GW, Somlo S, Dahl NK. TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD—A Novel Presentation. American Journal Of Kidney Diseases 2018, 72: 895-899. PMID: 29941221, DOI: 10.1053/j.ajkd.2018.05.006.Peer-Reviewed Original ResearchConceptsRenal thrombotic microangiopathyThrombotic microangiopathyTREX1 mutationsRetinal microangiopathyChronic kidney diseaseRepair exonuclease 1Whole-exome sequencingSignificant brainSymptomatic brainTREX1 variantsKidney involvementClinical presentationKidney diseaseCerebral leukodystrophyComplement dysregulationMicroangiopathyClinical importanceDiverse causesComplement regulationNovel presentationSubstantial proportionBrainSignificant proportionGenetic determinantsCause
2017
Slow Rise in Serum Creatinine Level in a Kidney Transplant Recipient 3 Years Post-Transplant
Bia MJ. Slow Rise in Serum Creatinine Level in a Kidney Transplant Recipient 3 Years Post-Transplant. Clinical Journal Of The American Society Of Nephrology 2017, 12: 1692-1694. PMID: 28336817, PMCID: PMC5628727, DOI: 10.2215/cjn.12691216.Peer-Reviewed Original Research
2012
A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report
Formica RN, Barrantes F, Asch WS, Bia MJ, Coca S, Kalyesubula R, McCloskey B, Leary T, Arvelakis A, Kulkarni S. A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. American Journal Of Kidney Diseases 2012, 60: 288-294. PMID: 22571868, DOI: 10.1053/j.ajkd.2012.04.008.Peer-Reviewed Original ResearchConceptsKidney transplantImprovement reportMultivariable Cox proportional hazards modelsCox proportional hazards modelKidney transplant candidacyMinimal listing criteriaGroup of patientsUniversity-based hospitalQuality improvement reportProportional hazards modelTransplant candidacyTransplant evaluationUNOS waitlistWaitlist placementTransplant centersComorbid conditionsMedian timeMultivariable analysisTransplant practitionersDialysis exposureFunctional statusWait listHazards modelPatientsRecipient candidates
2011
Should Living Kidney Donor Candidates with Impaired Fasting Glucose Donate?
Vigneault CB, Asch WS, Dahl NK, Bia MJ. Should Living Kidney Donor Candidates with Impaired Fasting Glucose Donate? Clinical Journal Of The American Society Of Nephrology 2011, 6: 2054-2059. PMID: 21784837, DOI: 10.2215/cjn.03370411.BooksConceptsTransplant centersLiving donorsDonor candidatesGreater riskImpaired glucose toleranceImpaired glucose metabolismDefinition of diabetesPotential living donorsKidney donor candidatesFuture diabetesKidney transplantMetabolic syndromeGlucose toleranceKidney donorsDonor screeningTransplant guidelinesHispanic ethnicityGlucose metabolismDiabetesHispanic individualsPotential donorsIFGRiskDonorsEthnicity
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response
2008
Effectiveness of an Integrated Ward-based Program in Preparing Medical Students to Care for Patients at the End of Life
Ellman MS, Rosenbaum JR, Cherlin E, Bia M. Effectiveness of an Integrated Ward-based Program in Preparing Medical Students to Care for Patients at the End of Life. American Journal Of Hospice And Palliative Medicine® 2008, 26: 18-23. PMID: 18955735, DOI: 10.1177/1049909108325437.Peer-Reviewed Original Research
2006
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006, 21: 1389-1394. PMID: 16431893, DOI: 10.1093/ndt/gfk058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmlodipineBlood Pressure DeterminationChi-Square DistributionDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionKidney Failure, ChronicKidney TransplantationLosartanMaleMiddle AgedProbabilityRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsRenal transplant recipientsPost-transplant periodEarly post-transplant periodARB useUse of ARBInitial therapyCCB groupImmediate post-transplant periodPost-transplant erythrocytosisPost-transplant hypertensionRisk of hyperkalaemiaPost-transplant managementSerum creatinine levelsChronic kidney diseaseII receptor blockersCalcium channel blockersNumber of patientsAldosterone systemARB groupKidney transplantationRenal transplantationTransplant recipientsCreatinine levelsRenal functionBlood pressure
2004
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period
Formica RN, Friedman AL, Lorber MI, Bia MJ. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period. Transplantation Proceedings 2004, 36: 2675-2678. PMID: 15621121, DOI: 10.1016/j.transproceed.2004.10.013.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersEarly posttransplant periodII receptor blockersCalcium channel blockersTreatment of hypertensionPosttransplant periodReceptor blockersEnzyme inhibitorsAcute renal dysfunctionAdministration of ACEAdult renal transplantsAppropriate clinical criteriaRenal transplant patientsGlomerular filtration rateType of transplantUse of ACESerum potassium concentrationAllograft functionPancreas transplantsRenal dysfunctionRenal transplantTransplant patientsSerum creatininePosttransplant erythrocytosisSerum potassiumRenal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection
Friedman AL, Goker O, Kalish MA, Basadonna GP, Kliger AS, Bia MJ, Lorber MI. Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection. International Urology And Nephrology 2004, 36: 451-456. PMID: 15783123, DOI: 10.1007/s11255-004-8685-2.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsOlder patientsYounger patientsChronologic ageActual patient survival ratesOlder renal transplant recipientsPrimary kidney transplantsYear graft survivalPatient survival ratesOrgan Transplant CenterAcute rejectionCadaveric recipientsEquivalent immunosuppressionGraft survivalImmunosuppression strategiesImmunosuppressive protocolsConsecutive recipientsKidney transplantDonor kidneysTransplant centersGeriatric patientsYounger recipientsOutcome analysisStudy group
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients